HUTCHMED (China) Limited (HK:0013) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
HUTCHMED (China) Limited has announced the launch of its novel cancer therapy, FRUZAQLA® (fruquintinib), in Japan, in partnership with Takeda. This milestone follows the approval by Japan’s Ministry of Health, Labour and Welfare, marking FRUZAQLA® as the first oral targeted treatment for metastatic colorectal cancer in Japan in over a decade. The drug, already available in the US, Europe, and China, highlights the strategic global expansion of HUTCHMED’s cancer treatment portfolio.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.
